CL2018002928A1 - Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. - Google Patents
Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.Info
- Publication number
- CL2018002928A1 CL2018002928A1 CL2018002928A CL2018002928A CL2018002928A1 CL 2018002928 A1 CL2018002928 A1 CL 2018002928A1 CL 2018002928 A CL2018002928 A CL 2018002928A CL 2018002928 A CL2018002928 A CL 2018002928A CL 2018002928 A1 CL2018002928 A1 CL 2018002928A1
- Authority
- CL
- Chile
- Prior art keywords
- ehmt1
- ehmt2
- amino
- inhibitors
- aryl
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 150000001875 compounds Chemical group 0.000 abstract 2
- -1 AMINO Chemical group 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 abstract 1
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 abstract 1
- 101000877314 Homo sapiens Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 abstract 1
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
SE DESCRIBEN COMPUESTOS DE ARILO O HETEROARILO SUSTITUIDOS CON AMINO; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y MÉTODOS DE TRATAMIENTO DE UN TRASTORNO (E.G., ANEMIA DREPANOCÍTICA) MEDIANTE LA INHIBICIÓN DE UNA ENZIMA METILTRANSFERASA SELECCIONADA ENTRE EHMT1 Y EHMT2, ADMINISTRANDO DICHO COMPUESTO O DICHA COMPOSICIÓN FARMACÉUTICA A UN SUJETO QUE LO NECESITE. TAMBIÉN SE DESCRIBE EL USO DE TALES COMPUESTOS EN INVESTIGACIÓN U OTROS FINES NO TERAPÉUTICOS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323602P | 2016-04-15 | 2016-04-15 | |
US201662348837P | 2016-06-10 | 2016-06-10 | |
US201662402997P | 2016-09-30 | 2016-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018002928A1 true CL2018002928A1 (es) | 2019-02-01 |
Family
ID=58664786
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002928A CL2018002928A1 (es) | 2016-04-15 | 2018-10-12 | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. |
CL2019000815A CL2019000815A1 (es) | 2016-04-15 | 2019-03-28 | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019000815A CL2019000815A1 (es) | 2016-04-15 | 2019-03-28 | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928). |
Country Status (24)
Country | Link |
---|---|
US (2) | US20170355712A1 (es) |
EP (1) | EP3442947B1 (es) |
JP (3) | JP7041070B2 (es) |
KR (2) | KR20230130747A (es) |
CN (1) | CN109153650A (es) |
AU (3) | AU2017250369A1 (es) |
BR (1) | BR112018071093A2 (es) |
CA (1) | CA3021062A1 (es) |
CL (2) | CL2018002928A1 (es) |
CO (1) | CO2018012181A2 (es) |
DK (1) | DK3442947T3 (es) |
ES (1) | ES2953512T3 (es) |
FI (1) | FI3442947T3 (es) |
HU (1) | HUE064145T2 (es) |
IL (3) | IL281319B2 (es) |
LT (1) | LT3442947T (es) |
MA (1) | MA44666A (es) |
MX (2) | MX2018012622A (es) |
PL (1) | PL3442947T3 (es) |
PT (1) | PT3442947T (es) |
SG (2) | SG10201913471VA (es) |
SI (1) | SI3442947T1 (es) |
TW (1) | TWI751155B (es) |
WO (1) | WO2017181177A1 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107847495A (zh) | 2015-05-06 | 2018-03-27 | 加利福尼亚大学董事会 | K‑Ras调节剂 |
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
EP3426245B1 (en) | 2016-03-07 | 2022-12-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
MX2018012541A (es) | 2016-04-15 | 2019-01-17 | Abbvie Inc | Inhibidores de bromodominios. |
US11278550B2 (en) | 2016-05-17 | 2022-03-22 | Duke University | Compositions and methods for the treatment of Prader-Willi syndrome |
CN116041346A (zh) * | 2016-12-19 | 2023-05-02 | Epizyme股份有限公司 | 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法 |
WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
WO2018195439A2 (en) * | 2017-04-20 | 2018-10-25 | The Regents Of The University Of California | K-ras modulators |
CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
KR102556744B1 (ko) | 2017-08-28 | 2023-07-18 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
CN111343988A (zh) * | 2017-10-17 | 2020-06-26 | Epizyme股份有限公司 | 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物 |
US20210213014A1 (en) * | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
IL310625A (en) * | 2017-10-18 | 2024-04-01 | Epizyme Inc | Methods for using EHMT2 inhibitors in the treatment or prevention of blood disorders |
CA3079273A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
EP3752491A4 (en) | 2018-02-15 | 2021-12-01 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS |
CN108822103A (zh) * | 2018-07-28 | 2018-11-16 | 刘凤娟 | 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用 |
CA3113235A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
JP7273172B2 (ja) | 2018-10-31 | 2023-05-12 | ギリアード サイエンシーズ, インコーポレイテッド | Hpk1阻害活性を有する置換6-アザベンゾイミダゾール化合物 |
MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
AU2020269469A1 (en) * | 2019-05-05 | 2021-12-09 | Regor Pharmaceuticals, Inc. | CDK inhibitors |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
GB201910608D0 (en) * | 2019-07-24 | 2019-09-04 | Enterprise Therapeutics Ltd | Compounds |
WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
PE20221905A1 (es) | 2019-10-11 | 2022-12-23 | Incyte Corp | Aminas biciclicas como inhibidoras de la cdk2 |
CA3163206A1 (en) * | 2019-11-27 | 2021-06-03 | Riken | G9a inhibitor |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
PE20230609A1 (es) | 2020-05-04 | 2023-04-13 | Amgen Inc | Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso |
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
CN111518015A (zh) * | 2020-05-20 | 2020-08-11 | 上海合全药物研发有限公司 | 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法 |
MX2023009685A (es) | 2021-02-19 | 2023-10-30 | Sudo Biosciences Ltd | Inhibidores de tyk2 y sus usos. |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
IL311999A (en) * | 2021-10-15 | 2024-06-01 | Tango Therapeutics Inc | New modulators of EHMT1 and EHMT2 and their therapeutic use |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2024019541A1 (ko) * | 2022-07-20 | 2024-01-25 | 일동제약(주) | 헤테로아릴 유도체 화합물 및 이의 용도 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
EP0585500A1 (en) * | 1992-09-04 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Diaryl piperazineacetamides as antimuscarinic agents |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
WO2003002544A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003032994A2 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
WO2006014420A1 (en) | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
JP5483874B2 (ja) | 2005-05-05 | 2014-05-07 | サノフィ−アベンティス・ユー・エス・エルエルシー | 安定なナノ粒子処方物 |
EP1910349A1 (en) | 2005-07-15 | 2008-04-16 | 4Sc Ag | 2-arylbenzothiazoles and uses thereof |
EP1746096A1 (en) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
WO2007038387A2 (en) | 2005-09-23 | 2007-04-05 | Yale University | Compounds and methods for the treatment of viruses and cancer |
CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
EP2021316A1 (en) | 2006-05-26 | 2009-02-11 | Abbott Laboratories | Inhibitors of polo-like kinases |
RU2010137300A (ru) | 2008-02-22 | 2012-03-27 | Ф. Хоффманн-Ля Рош Аг (Ch) | Модуляторы бета-амилоида |
SG2014015085A (en) * | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
WO2010017122A2 (en) * | 2008-08-05 | 2010-02-11 | Targegen Inc. | Methods of treating thalassemia |
BRPI0918056A2 (pt) | 2008-09-03 | 2015-08-11 | Bayer Cropscience Ag | Diaminopirimidinas substituídas por 4-alquila |
TW201040162A (en) * | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
PL2576541T3 (pl) | 2010-06-04 | 2016-10-31 | Pochodne aminopirymidyny jako modulatory lrrk2 | |
US20130244963A1 (en) * | 2010-09-30 | 2013-09-19 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
KR101682417B1 (ko) * | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
WO2013054351A1 (en) | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
WO2013033037A2 (en) | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Novel antiprion compounds |
WO2013070852A2 (en) * | 2011-11-08 | 2013-05-16 | Emory University | Compounds and compositions used to epigenetically transform cells and methods related thereto |
KR101452235B1 (ko) * | 2012-02-03 | 2014-10-22 | 서울대학교산학협력단 | 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 rage 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
EP2828250B1 (en) * | 2012-03-19 | 2021-03-10 | Imperial College Innovations Limited | Quinazoline compounds and their use in therapy |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
WO2014058921A2 (en) * | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
WO2015109109A1 (en) | 2014-01-15 | 2015-07-23 | Forum Pharmaceuticals Inc. | Fused morpholinopyrimidines and methods of use thereof |
JP6527534B2 (ja) * | 2014-06-16 | 2019-06-05 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダFundacion Para La Investigasion Medica Aplicada | ヒストンメチルトランスフェラーゼ及びdnaメチルトランスフェラーゼの二重阻害剤としての新規化合物 |
-
2017
- 2017-04-17 TW TW106112816A patent/TWI751155B/zh active
- 2017-04-17 IL IL281319A patent/IL281319B2/en unknown
- 2017-04-17 CA CA3021062A patent/CA3021062A1/en active Pending
- 2017-04-17 PL PL17720921.0T patent/PL3442947T3/pl unknown
- 2017-04-17 CN CN201780030129.9A patent/CN109153650A/zh active Pending
- 2017-04-17 WO PCT/US2017/027918 patent/WO2017181177A1/en active Application Filing
- 2017-04-17 MX MX2018012622A patent/MX2018012622A/es unknown
- 2017-04-17 SI SI201731402T patent/SI3442947T1/sl unknown
- 2017-04-17 FI FIEP17720921.0T patent/FI3442947T3/fi active
- 2017-04-17 JP JP2018553876A patent/JP7041070B2/ja active Active
- 2017-04-17 KR KR1020237028695A patent/KR20230130747A/ko not_active Application Discontinuation
- 2017-04-17 AU AU2017250369A patent/AU2017250369A1/en not_active Abandoned
- 2017-04-17 BR BR112018071093A patent/BR112018071093A2/pt active Search and Examination
- 2017-04-17 PT PT177209210T patent/PT3442947T/pt unknown
- 2017-04-17 IL IL307931A patent/IL307931A/en unknown
- 2017-04-17 SG SG10201913471VA patent/SG10201913471VA/en unknown
- 2017-04-17 DK DK17720921.0T patent/DK3442947T3/da active
- 2017-04-17 EP EP17720921.0A patent/EP3442947B1/en active Active
- 2017-04-17 MA MA044666A patent/MA44666A/fr unknown
- 2017-04-17 LT LTEPPCT/US2017/027918T patent/LT3442947T/lt unknown
- 2017-04-17 KR KR1020187032892A patent/KR102571679B1/ko active IP Right Grant
- 2017-04-17 SG SG11201808799SA patent/SG11201808799SA/en unknown
- 2017-04-17 HU HUE17720921A patent/HUE064145T2/hu unknown
- 2017-04-17 ES ES17720921T patent/ES2953512T3/es active Active
- 2017-05-22 US US15/601,888 patent/US20170355712A1/en not_active Abandoned
-
2018
- 2018-10-04 IL IL262140A patent/IL262140A/en unknown
- 2018-10-12 CL CL2018002928A patent/CL2018002928A1/es unknown
- 2018-10-15 MX MX2022010947A patent/MX2022010947A/es unknown
- 2018-11-13 CO CONC2018/0012181A patent/CO2018012181A2/es unknown
-
2019
- 2019-03-28 CL CL2019000815A patent/CL2019000815A1/es unknown
-
2020
- 2020-11-20 US US17/100,489 patent/US20210198277A1/en active Pending
-
2021
- 2021-10-07 AU AU2021245168A patent/AU2021245168B2/en active Active
-
2022
- 2022-03-10 JP JP2022036728A patent/JP7420847B2/ja active Active
-
2024
- 2024-01-11 JP JP2024002232A patent/JP2024045202A/ja active Pending
- 2024-01-25 AU AU2024200464A patent/AU2024200464A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002928A1 (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. | |
ZA201906822B (en) | Indole ahr inhibitors and uses thereof | |
EA202091186A1 (ru) | ИНГИБИТОРЫ KRas G12C | |
UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
CO2018000668A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
CO2019006787A2 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos | |
TR201901445T4 (tr) | Il2rbeta/yaygın gamma zinciri antikorları. | |
EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
CO2018000631A2 (es) | Compuestos bicíclicos como inhibidores de atx | |
CO2017011152A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca. | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
EA201691916A1 (ru) | Биарильные ингибиторы киназы | |
EA201890052A1 (ru) | Регуляторы nrf2 | |
EA201790649A1 (ru) | Бензилзамещенные индазолы в качестве ингибиторов bub 1 | |
AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
CL2015003569A1 (es) | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct | |
MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
EA201890247A1 (ru) | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин | |
BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2019015744A (es) | Composiciones farmaceuticas. | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
EA201991029A1 (ru) | Ингибиторы magl | |
MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. |